Mepolizumab for COPD Hospital Eosinophilic admissions Pragmatic trial1
Research type
Research Study
Full title
A Randomised Controlled Trial of Mepolizumab Initiated During Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD
IRAS ID
255237
Contact name
Christopher Brightling
Contact email
Sponsor organisation
University of Leicester
Eudract number
2018-003924-35
Duration of Study in the UK
2 years, 4 months, 28 days
Research summary
This trial is taking part in one hospital and is looking at comparing a medication called ‘mepolizumab’ with a placebo in patients who are admitted to hospital following an exacerbation of their COPD.
Treatment will be provided via an injection once a month for approximately 11 months. Participants will receive either mepolizumab or placebo. Which one they receive will be chosen at random and the result will not be known to the participant or the study team.
Participants will be expected to attend 13 study visits at the Respiratory Biomedical Research Centre at the Glenfield General Hospital, Leicester where they will undergo a series of tests and assessments which aim to understand how the treatment they receive affects their health status, well-being and future exacerbations of COPD.
This study is sponsored by the University of Leicester and coordinated by the Leicester Clinical Trials (LCTU).
REC name
East of England - Essex Research Ethics Committee
REC reference
19/EE/0286
Date of REC Opinion
18 Nov 2019
REC opinion
Further Information Favourable Opinion